A model for decoding resistance in precision oncology: acquired resistance to FGFR inhibitors in cholangiocarcinoma
Love Goyal(Cancer Research UK), D.C. Bensen(Electronic BioSciences (United States)), Rachna T. Shroff(University of Arizona), C.T. Chen(Palo Alto University), Isaac Hoffman(Electronic BioSciences (United States)), Mitesh J. Borad(Mayo Clinic in Arizona), Tim Harris(Electronic BioSciences (United States)), James M. Cleary(Dana-Farber Cancer Institute), Robin Kate Kelley(University of California, San Francisco), Kari Nelson(Electronic BioSciences (United States)), Daniel DiToro(Brigham and Women's Hospital), Hiroshi Hirai(Taiho Pharmaceutical (Japan)), Nataliya V. Uboha(University of Wisconsin Carbone Cancer Center), Keith T. Flaherty(Massachusetts General Hospital), Thomas B. Karasic(Hospital of the University of Pennsylvania), Laxmi Parida(IBM (United States)), Hiroshi Sootome(Taiho Pharmaceutical (Japan)), Jochen Maurer(Universitätsklinikum Aachen), James R. Stone(Harvard University), Umair Majeed(Mayo Clinic in Florida), Jean Fan(Harvard University), C. Pinto(Harvard University), Brian P. Danysh(Broad Institute), P. Peng, Avinash Kambadakone(Harvard University), Islam Baiev(Massachusetts General Hospital), John D. Gordan(University of California, San Francisco), Caixia Sun(Jilin University), Bo Lin(Virginia Mason Medical Center), Frank Wu, J.E. Berchuck(Harvard University), Ignaty Leshchiner(Broad Institute), Kabir Mody(Mayo Clinic in Florida), M. M. Javle(The University of Texas MD Anderson Cancer Center), D. Vasseur(Inserm), N. Damjanov(University of Pennsylvania), Sylvia A. Reyes(Duke University), Charlotte S. Walmsley(Harvard University), S. Iyer(Electronic BioSciences (United States)), Ramakrishnan Iyer(Roswell Park Comprehensive Cancer Center), Andrew X. Zhu(Massachusetts General Hospital), Karen Zhang(UCSF Helen Diller Family Comprehensive Cancer Center), Liang Li(Chengdu University), Sudipta Saha(Fred Hutch Cancer Center), E Martin(Broad Institute), William Proctor Harris(University of Washington), E. Wehrenberg-Klee(Harvard University), H. Wang, Francesco Facchinetti(Inserm)
Cited by 33
Related Papers
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Dissecting the multicellular ecosystem of metastatic melanoma by single-cell RNA-seq
|Science|2016|5.2k
Inhibition of Mutated, Activated BRAF in Metastatic Melanoma
|New England Journal of Medicine|2010|3.5k